As an Infectious Diseases Physician Scientist, my research has been focused on improving the lives of HIV-infected individuals by imporving long-term outcomes of infection and treatment. This work includes collaborations with the AIDS Clinical Trials Group (ACTG), the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) group, and teams of multi-disciplinary investigators, and has bridged outcomes-epidemiology research, translational research, and clinical trials. This work has led to successful NIH-funded grants on which I have served as principal investigator or co-investigator. I have a strong track record of successfully leading and contributing to collaborative clinical-translational research in inflammation, oxidative stress, and genomics that has produced peer-reviewed publications of high relevance.


The following timeline graph is generated from all co-authored publications.

  1. An association between adiposity and serum levels of macrophage inflammatory protein-1α and soluble CD14 in HIV-infected adults: results from a cross-sectional study. Koethe JR, Bian A, Shintani AK, Wester CW, Erdem H, Hulgan T (2013) Antivir Ther 18(5): 729-33
    › Primary publication · 23748193 (PubMed) · PMC3923367 (PubMed Central)
  2. Circulating interleukin-6, soluble CD14, and other inflammation biomarker levels differ between obese and nonobese HIV-infected adults on antiretroviral therapy. Koethe JR, Dee K, Bian A, Shintani A, Turner M, Bebawy S, Sterling TR, Hulgan T (2013) AIDS Res Hum Retroviruses 29(7): 1019-25
    › Primary publication · 23469772 (PubMed) · PMC3685684 (PubMed Central)
  3. Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. Holzinger ER, Hulgan T, Ellis RJ, Samuels DC, Ritchie MD, Haas DW, Kallianpur AR, Bloss CS, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, McCutchan JA, Morgello S, Simpson DM, Franklin DR, Rosario D, Selph D, Letendre S, Grant I, CHARTER Group (2012) J Neurovirol 18(6): 511-20
    › Primary publication · 23073667 (PubMed) · PMC3587171 (PubMed Central)
  4. T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384. Hulgan T, Robbins GK, Kalams SA, Samuels DC, Grady B, Shafer R, Murdock DG, Selph D, Haas DW, Pollard RB, AIDS Clinical Trials Group (2012) PLoS One 7(8): e43803
    › Primary publication · 22970105 (PubMed) · PMC3433792 (PubMed Central)
  5. Active cocaine use is associated with lack of HIV-1 virologic suppression independent of nonadherence to antiretroviral therapy: use of a rapid screening tool during routine clinic visits. Rasbach DA, Desruisseau AJ, Kipp AM, Stinnette S, Kheshti A, Shepherd BE, Sterling TR, Hulgan T, McGowan CC, Qian HZ (2013) AIDS Care 25(1): 109-17
    › Primary publication · 22670566 (PubMed) · PMC3443534 (PubMed Central)
  6. Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases. Haas DW, Kuritzkes DR, Ritchie MD, Amur S, Gage BF, Maartens G, Masys D, Fellay J, Phillips E, Ribaudo HJ, Freedberg KA, Petropoulos C, Manolio TA, Gulick RM, Haubrich R, Kim P, Dehlinger M, Abebe R, Telenti A, Workshop Pharmacogenomics-A Path Towards Personalized HIV Care (2011) HIV Clin Trials 12(5): 277-85
    › Primary publication · 22180526 (PubMed) · PMC3322423 (PubMed Central)
  7. Serum leptin level mediates the association of body composition and serum C-reactive protein in HIV-infected persons on antiretroviral therapy. Koethe JR, Bian A, Shintani AK, Boger MS, Mitchell VJ, Erdem H, Hulgan T (2012) AIDS Res Hum Retroviruses 28(6): 552-7
    › Primary publication · 22145933 (PubMed) · PMC3358098 (PubMed Central)
  8. Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS clinical trials group study 384. Grady BJ, Samuels DC, Robbins GK, Selph D, Canter JA, Pollard RB, Haas DW, Shafer R, Kalams SA, Murdock DG, Ritchie MD, Hulgan T, ACTG 384 and DACS 250 Study Teams (2011) J Acquir Immune Defic Syndr 58(4): 363-70
    › Primary publication · 21792066 (PubMed) · PMC3204178 (PubMed Central)
  9. Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts. McGowan CC, Weinstein DD, Samenow CP, Stinnette SE, Barkanic G, Rebeiro PF, Sterling TR, Moore RD, Hulgan T (2011) PLoS One 6(4): e18462
    › Primary publication · 21541016 (PubMed) · PMC3081810 (PubMed Central)
  10. The relationship between injection and noninjection drug use and HIV disease progression. Qian HZ, Stinnette SE, Rebeiro PF, Kipp AM, Shepherd BE, Samenow CP, Jenkins CA, No P, McGowan CC, Hulgan T, Sterling TR (2011) J Subst Abuse Treat 41(1): 14-20
    › Primary publication · 21349679 (PubMed) · PMC3110534 (PubMed Central)